New report provides important benchmark tool for deal-makers - Potential high returns for companies licensing in and out early-stage products YORK, UNITED KINGDOM (27 December 2003)
YORK, UNITED KINGDOM December 26 2003–Early stage partnering is still in high demand. Licensees are increasingly seeking earlier stage compounds to supplement internal R&D efforts. Licensors, in particular emerging pharmaceutical and biotech companies, have two key strategic reasons for entering into deals ? one is to provide short term financing and endorsement of their technologies, the other is to support changes in their business models as companies move from being simple suppliers of technology to fully integrated pharmaceutical companies (FIPCOs).
Within a secretive industry, it is difficult for pharmaceutical and biotech companies to obtain accurate benchmarks for deal terms. Most companies, whilst wishing to explore creative deal making options, still wish to reassure management and shareholders that the offer from the other side is competitive with industry trends. Such data has not been readily available - until the publication of ?Early Stage and Discovery Deals: Strategy, Structure and Payment Terms?, the latest report from the Bridgehead Pharmalicensing Group.
The report, by Pharmalicensing founder Steve Poile and Head of Publishing Suzanne Elvidge, is an in-depth review of licensing structures and strategies for discovery and preclinical deals, supported with case studies and deals data analysis. The publication includes press releases and the text of contracts from real early stage deals, allowing the reader to explore the actual deal terms in use in the industry today.
?Early-stage partnering is a core component of both biotech and pharmaceutical business strategy, allowing access to promising new and emerging technologies, even though the risk of compound failure is high. Deal complexity is increasing both in terms of financial reward structures and exchange of non-monetary capabilities. We have produced a report which breaks down this complexity, providing guidelines for dealmakers in this highly competitive area?, according to author Steve Poile.
?By providing real-world data and case studies, this report will help dealmakers to benchmark future deal structures and strategies?, co-author Suzanne Elvidge added.
Brief contents
Executive summary
Why do companies partner early-stage compounds?
The evolving role of partnering in biopharmaceutical development
Early-stage deal strategies and structures
Payment strategies
How to make the right deal
Deal terms and trends - a data analysis of early-stage deals
Appendices
The report is available for ?1200/$1950/?1950 , in print or PDF format. For further details, please go to www.pharmalicensing.com/reports or call +44 1904 520464.
About Steve Poile
Steve Poile is the founder of Pharmalicensing and a director of the Bridgehead Pharmalicensing Group. Steve was Technology Licensing Manager and Competitor Intelligence Manager for Reckitt Benckiser Pharmaceutical Division, where he was responsible for sourcing and securing novel therapeutic and drug delivery technologies, as well as developing the company?s competitor intelligence capability. Previously, Steve was a research scientist at SmithKline Beecham, working in the areas of dermatology, gastroenterology and drug delivery. Steve was responsible for founding Pharmalicensing in 1998. Steve is actively involved in assisting client companies who seek business partners in the global biopharmaceutical sector, to achieve their partnering goals. He is an active member of the Licensing Executive Society, and speaks regularly on the topics of finding partners and deal terms.
About Suzanne Elvidge
Suzanne Elvidge is the Head of Publishing at the Bridgehead Pharmalicensing Group. She is the Editor of Partnering Focus, Pharmalicensing?s magazine for the partnering community, and the company?s weekly electronic newsletter, as well as writing and commissioning in-depth industry and legal reports. Suzanne has worked in medical and scientific publishing for 13 years, including six years at IMS Health on the pharmaceutical R&D newsletter R&D focus, and three years in medical education and communications with Healthworld, working on a variety of client accounts in a wide range of therapeutic areas.
About the Bridgehead Pharmalicensing Group
The Bridgehead Pharmalicensing Group, the result of a merger between Pharmalicensing Ltd and Bridgehead Technologies Ltd in May 2003, is a full service business supplying licensing, partnering and consulting services to companies worldwide, ranging from small biotechnology start-ups to leading pharmaceutical and medical companies. Pharmalicensing is the leading multi-channel business marketing tool for biopharma companies.
No comments yet. Be the first.
Leave a reply
New report provides important benchmark tool for deal-makers - Potential high returns for companies licensing in and out early-stage products YORK, UNITED KINGDOM (27 December 2003)
YORK, UNITED KINGDOM December 26 2003–Early stage partnering is still in high demand. Licensees are increasingly seeking earlier stage compounds to supplement internal R&D efforts. Licensors, in particular emerging pharmaceutical and biotech companies, have two key strategic reasons for entering into deals ? one is to provide short term financing and endorsement of their technologies, the other is to support changes in their business models as companies move from being simple suppliers of technology to fully integrated pharmaceutical companies (FIPCOs).
Within a secretive industry, it is difficult for pharmaceutical and biotech companies to obtain accurate benchmarks for deal terms. Most companies, whilst wishing to explore creative deal making options, still wish to reassure management and shareholders that the offer from the other side is competitive with industry trends. Such data has not been readily available - until the publication of ?Early Stage and Discovery Deals: Strategy, Structure and Payment Terms?, the latest report from the Bridgehead Pharmalicensing Group.
The report, by Pharmalicensing founder Steve Poile and Head of Publishing Suzanne Elvidge, is an in-depth review of licensing structures and strategies for discovery and preclinical deals, supported with case studies and deals data analysis. The publication includes press releases and the text of contracts from real early stage deals, allowing the reader to explore the actual deal terms in use in the industry today.
?Early-stage partnering is a core component of both biotech and pharmaceutical business strategy, allowing access to promising new and emerging technologies, even though the risk of compound failure is high. Deal complexity is increasing both in terms of financial reward structures and exchange of non-monetary capabilities. We have produced a report which breaks down this complexity, providing guidelines for dealmakers in this highly competitive area?, according to author Steve Poile.
?By providing real-world data and case studies, this report will help dealmakers to benchmark future deal structures and strategies?, co-author Suzanne Elvidge added.
Brief contents
Executive summary
Why do companies partner early-stage compounds?
The evolving role of partnering in biopharmaceutical development
Early-stage deal strategies and structures
Payment strategies
How to make the right deal
Deal terms and trends - a data analysis of early-stage deals
Appendices
The report is available for ?1200/$1950/?1950 , in print or PDF format. For further details, please go to www.pharmalicensing.com/reports or call +44 1904 520464.
About Steve Poile
Steve Poile is the founder of Pharmalicensing and a director of the Bridgehead Pharmalicensing Group. Steve was Technology Licensing Manager and Competitor Intelligence Manager for Reckitt Benckiser Pharmaceutical Division, where he was responsible for sourcing and securing novel therapeutic and drug delivery technologies, as well as developing the company?s competitor intelligence capability. Previously, Steve was a research scientist at SmithKline Beecham, working in the areas of dermatology, gastroenterology and drug delivery. Steve was responsible for founding Pharmalicensing in 1998. Steve is actively involved in assisting client companies who seek business partners in the global biopharmaceutical sector, to achieve their partnering goals. He is an active member of the Licensing Executive Society, and speaks regularly on the topics of finding partners and deal terms.
About Suzanne Elvidge
Suzanne Elvidge is the Head of Publishing at the Bridgehead Pharmalicensing Group. She is the Editor of Partnering Focus, Pharmalicensing?s magazine for the partnering community, and the company?s weekly electronic newsletter, as well as writing and commissioning in-depth industry and legal reports. Suzanne has worked in medical and scientific publishing for 13 years, including six years at IMS Health on the pharmaceutical R&D newsletter R&D focus, and three years in medical education and communications with Healthworld, working on a variety of client accounts in a wide range of therapeutic areas.
About the Bridgehead Pharmalicensing Group
The Bridgehead Pharmalicensing Group, the result of a merger between Pharmalicensing Ltd and Bridgehead Technologies Ltd in May 2003, is a full service business supplying licensing, partnering and consulting services to companies worldwide, ranging from small biotechnology start-ups to leading pharmaceutical and medical companies. Pharmalicensing is the leading multi-channel business marketing tool for biopharma companies.
No comments yet. Be the first.
Leave a reply